IP Library › Patent Application 17022494
Patent Application
App. No. 17/022,494

TREATMENT OF SYNGAP1 ENCEPHALOPATHY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/022,494
Abstract

The present technology relates to methods of treating SYNGAP1 encephalopathy by transdermally administering an effective amount of cannabidiol (CBD) to the subject, wherein a SYNGAP1 symptom is treated in the subject.

Claims (23)

1 . A method of treating SYNGAP1 encephalopathy, the method comprising:

transdermally administering an effective amount of cannabidiol (CBD) to the subject, wherein a SYNGAP1 symptom is treated in the subject.

2 . The method of claim 1 , wherein the effective amount of CBD is 250, 500, 750, or 1000 mg total daily.

3 . The method of claim 1 , wherein the effective amount of CBD is 750 mg total daily.

4 . The method of claim 1 , wherein the effective amount of CBD is 1000 mg total daily.

5 . The method according to claim 1 , wherein the treated SYNGAP1 symptom is one or more behavioral problems.

6 . The method of claim 5 , wherein the treatment of one or more behavioral problems includes a decrease in one or more behavioral problems.

7 . The method of claim 6 , wherein the one or more behavioral problems comprise social avoidance, attention deficits, impulsivity, mood abnormalities, inattention, impulsivity, or physical aggression.

8 . The method according to claim 1 , wherein the treated SYNGAP1 symptom is seizures.

9 . The method of claim 8 , wherein treatment includes a decrease from about 25% to about 45% in SYNGAP1 seizures.

10 . The method of claim 9 , wherein the SYNGAP1 seizures are at least one of focal impaired awareness seizures (FIAS) or atonic seizures (AT).

11 . The method according to claim 1 , wherein two or more SYNGAP1 symptoms are treated.

12 . The method of claim 11 , wherein the two or more treated SYNGAP1 symptoms are behavioral problems and SYNGAP1 seizures.

13 . The method of claim 12 , wherein the treatment of behavioral problems includes a decrease in one or more behavioral problems, and wherein the treatment of SYNGAP1 seizures includes a decrease from about 25% to about 45% in SYNGAP1 seizures.

14 . The method of claim 13 , wherein the behavioral problems comprise social avoidance, attention deficits, impulsivity, mood abnormalities, inattention, impulsivity, or physical aggression.

15 . The method of claim 13 , wherein the SYNGAP1 seizures are at least one of focal impaired awareness seizures (FIAS) or atonic seizures (AT).

16 . The method according to claim 1 , wherein treatment includes an improvement in every day satisfaction and well-being.

17 . The method according to claim 1 , wherein treatment includes an improvement in cognition and awareness.

18 . The method according to claim 1 , wherein the treatment includes a meaningful monthly reduction in focal impaired awareness seizures and convulsive seizures.

19 . The method according to claim 1 , wherein the CBD is administered in a single daily dose or in two daily doses.

20 . The method according to claim 1 , wherein the CBD is a synthetic CBD.

21 . The method of claim 20 , wherein the CBD is purified.

22 . The method according to claim 1 , wherein the CBD is botanically derived.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 10, 2020
From: SEBREE, TERRI; MESSENHEIMER, JOHN; GUTTERMAN, DONNA
To: ZYNERBA PHARMACEUTICALS, INC.
Reel/Frame 054323/0349 →